Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific survival and tumor recurrence. Dr. Ari Hakimi MD, from Memorial Sloan-Kettering Cancer Center in New York gave the 2014 ASCO Genitourinary Cancers Symposium his group’s findings about the MET oncogene variant which they found to be associated with poor outcomes. He noted that the mechanism made clear by this research could provide a basis for drug targeting in the future while already providing doctors with their first clinically useful molecular biomarker.

CONTACT:
Dr. A Ari Hakimi MD
Department of Surgery, Urology Service,
Memorial Sloan-Kettering Cancer Center
New York
NY 10065

SOURCE:
Abstract number: 395
Title:
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.

Citation:
J Clin Oncol 32, 2014 (suppl 4; abstr 395)

Author(s):
A. Ari Hakimi, Irina Ostrovnaya, Anders Jacobsen, Jonathan A. Coleman, Paul Russo, Roy Mano, Alexander Sankin, Robert John Motzer, Mark Purdue, Mark Pomerantz, Matthew L Freedman, Toni K. Choueiri, James Hsieh, Robert J. Klein; Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Dana-Farber Cancer Institute, Boston, MA; Broad Institute, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

LINK: http://meetinglibrary.asco.org/content/124087-142